[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585837":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":76,"collaborators":78,"id":93,"slug":10,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":10,"enrollmentInfo":101,"targetDuration":104,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":121,"whyStopped":10,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Universität des Saarlandes","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"European SLD Registry",null,"The EU-SLD registry comprises patients from 18 european countries and a study cohort of n=8.984 with most recent cases recruited in the prospective LITMUS cohort study. Now followed up as part of the LOVE Study in the EU-LIVERAIM project.",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"Jörn M. Schattenberg, MD","CONTACT","+49684116","15027","gastroenterologie@uks.eu",[20,36,47,61],{"facility":21,"status":10,"city":22,"state":10,"zip":23,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Hôpital de la Pitié Salpêtrière","Paris","75013","France",{"type":26,"coordinates":27},"Point",[28,29],2.3488,48.85341,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":34,"phoneExt":10,"email":35},"Scientific Affaires Officer, PhD, MPH","0033","j.medvedovic@ihuican.org",{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":46,"contacts":10},"University Medical Center Saarland, Department of Internal Medicine II","Homburg","Saarland","66421","Germany",{"type":26,"coordinates":43},[44,45],7.33867,49.32637,{"lat":45,"lon":44},{"facility":48,"status":10,"city":49,"state":10,"zip":10,"country":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Division of Gastroenterology, Department of Medical Sciences, University of Turin","Turin","Italy",{"type":26,"coordinates":52},[53,54],7.68682,45.07049,{"lat":54,"lon":53},[57],{"name":58,"role":15,"phone":59,"phoneExt":10,"email":60},"Division of Gastroenterology, Department of Medical Sciences","0039 11 6333272","elisabetta.bugianesi@unito.it",{"facility":62,"status":10,"city":63,"state":10,"zip":64,"country":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Translational & Clinical Research Institute Faculty of Medical Sciences","Newcastle upon Tyne","NE2 4HH","United Kingdom",{"type":26,"coordinates":67},[68,69],-1.61396,54.97328,{"lat":69,"lon":68},[72],{"name":73,"role":15,"phone":74,"phoneExt":10,"email":75},"Kristy Wonders","+44","SLD.Registry@newcastle.ac.uk",{"type":77,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[79,81,83,85,87,89,91],{"name":80,"class":6},"Universitatsmedizin Mainz - 1. Medizinische Klinik",{"name":82,"class":6},"Newcastle University",{"name":84,"class":6},"Barcelona Institute for Global Health",{"name":86,"class":6},"Odense University Hospital",{"name":88,"class":6},"Hospital Clinic of Barcelona",{"name":90,"class":6},"Assistance Publique - Hôpitaux de Paris",{"name":92,"class":6},"University of Turin, Italy","100585837",false,"NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)","ALL","18 Years",{"count":102,"type":103},30000,"ESTIMATED","10 Years","OBSERVATIONAL","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[108,109,110,111],"Steatotic Liver Disease","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)","ALD - Alcoholic Liver Disease",[113,114,115,116,117,118,119,120],"MASH","SLD","NITs","MASLD","ALD","MetALD","Metabolism","Liver","NOT_YET_RECRUITING","2025-03-26",{"date":124,"type":125},"2025-04-02","ACTUAL",{"date":127,"type":103},"2025-04-15",{"date":129,"type":103},"2035-12-31",{"name":5,"class":6},4]